Morpholine Amide SSTR4 Agonists for Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective somatostatin receptor subtype 4 (SSTR4) agonists that exhibit high stability, permeability, and oral efficacy, with reduced side effects due to high selectivity for SSTR4 over other receptor subtypes, particularly SSTR1, to effectively treat medical disorders related to SSTR4.
Innovation Solution
Development of morpholine and 1,4-oxazepane amide derivatives that act as agonists for SSTR4, providing high metabolic stability and selectivity, along with their physiologically acceptable salts, hydrates, and pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-peptidic SSTR4 agonists are developed, then oral efficacy and metabolic stability are improved, but selectivity over other receptor subtypes (particularly SSTR1) deteriorates
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions of the core structure. Formula (I) uses targeted substitutions (R1 at position 2, W and R3 groups on the aromatic ring) to achieve selective binding to SSTR4 while maintaining metabolic stability. This localized modification approach allows differentiation between SSTR4 and other subtypes through specific molecular interactions at key positions.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types (R1 = H or C1-6 alkyl; W = various aromatic/heteroaromatic groups; R3 = various substituents) and structural parameters (m, p, q values defining ring substitution patterns). These parameter variations enable optimization of both selectivity and metabolic stability, transforming a non-selective scaffold into a selective SSTR4 agonist with improved pharmacokinetic properties.
2Object-affected harmful factors
If high selectivity for SSTR4 is achieved, then side effects are reduced, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: a core morpholine or 1,4-oxazepane amide structure, an aromatic/W substituent system, and specific R1, R3 side chains. This modular segmentation allows independent optimization of each segment for selectivity while controlling overall complexity. The segmented approach enables systematic structure-activity relationship studies to achieve SSTR4 selectivity without excessive structural complexity.
3Ease of operation
If oral efficacy is improved, then bioavailability increases, but metabolic stability may deteriorate
Solution Approach 1:
The patent applies composite material principles by combining the morpholine or 1,4-oxazepane amide core with specific aromatic/W groups and substituent patterns that provide both oral bioavailability and metabolic stability. The composite structure integrates hydrophilic and lipophilic components, along with metabolically stable aromatic rings and heterocycles, creating a balanced molecule that achieves both oral efficacy and resistance to metabolic degradation.
Data Source
AI summary
The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.